Is IndiTreat right for you as a cancer patient?
IndiTreat® could help your doctor choose a better cancer treatment for you
There are many forms of cancer, and an individual patient’s cancer might respond to certain drugs but not to others. For some conditions, IndiTreat® could help your doctor choose the right treatment for you, and avoid the ones that are less likely to work.
IndiTreat has received CE validation for testing drugs on colorectal cancer. This means that cancer clinics in the EU and the UK can order the test for this disease.
Medical treatment of solid cancers are usually based on guidelines from established, international cancer societies. Treatment begins with a first line therapy. If you are resistant to the drug or experience intolerable side effects, treatment is modified to a second line therapy involving a different drug or drug combination. If second line therapy is ineffective, there is rarely more help to be gained from guidelines and subsequent treatment may be experimental or based on your doctor’s experience.
In the current situation, IndiTreat® testing might be considered by your doctor after an ineffective second line therapy and if a tumor biopsy (removing a small sample of the. tumor) is possible. You can ask your doctor if it is possible to get an IndiTreat® test earlier. Even in guidelines for first line therapy, there are choices that your oncologist makes, where IndiTreat can help make his choice of treatment.
To ask your doctor if IndiTreat is appropriate for you, download this document and share it with your doctor or oncologist.
Introducing IndiTreat® from 2cureX
Please contact 2cureX for more information
September 15, 2021 at 15:00 (CET)
Interview with CEO Fernando Andreu (organized by Mangold) Open participation. Details provided later.
September 23, 2021
CSO Ole Thastrup will speak at the conference “Week of Health and Innovation 2021” in Odense, Denmark
September 28, 2021
Redeye Medtech & Diagnostics Investor meeting
September 29, 2021
Mangold Investor Lunch